LENZ Therapeutics, Inc. LENZ
- Market cap
- $117.4M
- P/E
- 0.0×
Follow LENZ
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | 56.77 | 14.49 | 11.13 | 14.42 | 15.70 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | 238.00 | 93.73 | 24.01 | 38.93 | 50.40 |
High Price
|
|||
| — | — | — | — | 27 | 69 | 120 | 6 | 42 | 152 |
Employees
|
|||
| — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | 19 |
Revenue
|
|||
| — | — | — | — | 0.00% | 0.00% | 0.00% | — | — | 97.81% |
Gross Margin
|
|||
| — | — | — | 0 | (68) | (71) | (101) | (70) | (50) | (82) |
EBT
|
|||
| — | — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (427.62%) |
EBT Margin
|
|||
| — | 0 | — | 0 | (68) | (71) | (101) | (70) | (50) | (82) |
Net Income
|
|||
| — | — | — | — | 0 | 1 | 1 | (1) | 0 | 0 |
Depreciation
|
|||
| — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.66 |
Revenue/Sh
|
|||
| — | — | — | 0.00 | (209.49) | (17.14) | (12.88) | (35.72) | (2.34) | (2.85) |
Earnings/Sh
|
|||
| — | — | — | 0.00 | (26.72) | (12.79) | (11.22) | (30.82) | (2.79) | (2.40) |
Cash Flow/Sh
|
|||
| — | — | — | 0.00 | (4.73) | (1.39) | (0.84) | (0.02) | (0.02) | (0.03) |
Capex/Sh
|
|||
| — | — | — | 0.00 | (31.45) | (14.18) | (12.06) | (30.84) | (2.81) | (2.43) |
Free CF/Sh
|
|||
| — | — | — | 0.00 | (200.39) | 92.93 | 37.79 | (47.33) | 9.59 | 9.87 |
Book Value/Sh
|
|||
| — | — | — | 0 | 0 | 4 | 8 | 2 | 21 | 29 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | 0.00 |
PE Ratio
|
|||
| — | — | — | — | — | — | — | — | — | 0.00 |
PS Ratio
|
|||
| — | — | — | — | — | — | — | — | — | 1.62 |
PB Ratio
|
|||
| — | — | — | — | — | — | — | — | — | 0.00 |
EV/Sales
|
|||
| — | — | — | — | — | — | — | — | — | (2.46) |
EV/FCF
|
|||
| — | — | — | 0 | (9) | (53) | (88) | (60) | (59) | (69) |
Op' Cash Flow
|
|||
| — | — | — | — | (2) | (6) | (7) | 0 | 0 | (1) |
Capex
|
|||
| — | — | — | 0 | (10) | (59) | (95) | (60) | (60) | (70) |
FCF
|
|||
| — | — | — | (2) | (11) | 370 | 262 | 49 | 202 | 280 |
Working Cap'
|
|||
| — | — | — | 2 | — | — | 4 | — | — | — |
Total Debt
|
|||
| — | — | — | 2 | (20) | (377) | (264) | (66) | (209) | (292) |
Net Debt
|
|||
| — | — | — | (2) | (65) | 384 | 296 | (93) | 204 | 284 |
Sh' Equity
|
|||
| — | — | — | (3,633.33%) | (605.88%) | (33.33%) | (27.92%) | (35.67%) | (34.84%) | (31.52%) |
ROA
|
|||
| — | — | — | 0.00% | 0.00% | (534.02%) | (205.64%) | 0.00% | 0.00% | 0.00% |
ROIC
|
|||
| — | — | — | 0.32% | 202.21% | (44.41%) | (29.71%) | (68.74%) | (89.37%) | (33.63%) |
ROE
|
|||
LENZ Therapeutics, Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| OKUR OnKure Therapeutics, Inc. | $118.7M | 0.0× | Compare |
| NTRB Nutriband Inc. | $115.2M | 0.0× | Compare |
| CBUS Cibus, Inc. | $114.6M | 0.0× | Compare |
| AARD Aardvark Therapeutics, Inc. | $121.5M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| COYA Coya Therapeutics, Inc. | $121.5M | 0.0× | Compare |
| VTVT vTv Therapeutics Inc. | $121.5M | 0.0× | Compare |
| KZIA Novogen Limited | $111.8M | 0.0× | Compare |
| VANI Vivani Medical, Inc. | $111.0M | 0.0× | Compare |
LENZ Therapeutics, Inc. (LENZ) key facts
- LENZ Therapeutics, Inc. (LENZ) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- LENZ Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $19.1 million.
- As of September 25, 2026, LENZ traded at $3.92, a market capitalization of $117.4 million.
- Return on equity was −33.6% and debt-to-equity 0.00.
LENZ Therapeutics, Inc. (LENZ) Latest News
12 Aug
LENZ Therapeutics reported Q2 2026 earnings call highlights centered on strong VIZZ launch momentum. VIZZ launch momentum signals major product success likely to shift company trajectory and investor views.
11 Aug
LENZ Therapeutics Q2 2026 earnings call covered financial results and future outlook. Earnings call delivers financial metrics and guidance that can influence near-term investor sentiment and stock movement.
LENZ Therapeutics Q2 earnings call covered financial results, operational updates and outlook for the company. Q2 earnings provide financial and strategic updates that moderately affect near-term market views.
LENZ Therapeutics reported second quarter 2026 financial results including revenue, expenses and net loss figures along with updates on product development, clinical trials and corporate milestones. Quarterly earnings and pipeline updates typically drive moderate shifts in valuation and near-term investor views.
6 Jul
LENZ Therapeutics launches telehealth prescribing option for VIZZ to treat presbyopia and accelerate patient access. Telehealth prescribing expands VIZZ access and supports increased product adoption.
24 Jun
LENZ Therapeutics grants Arrotex Pharmaceuticals exclusive rights to commercialize VIZZ™ in Australia and New Zealand. Regional licensing deal expands VIZZ™ revenue potential in Australia and New Zealand with limited global scope.
8 Jun
LENZ Therapeutics partners with a China-based firm to commercialize its presbyopia drug VIZZ in that market. China partnership expands VIZZ reach into a major new market for LENZ.
7 Jun
LENZ Therapeutics announced that Everest Medicines acquired rights to develop and commercialize VIZZ® (LNZ100) in Greater China. Partnership expands VIZZ access to Greater China market with potential revenue impact but limited overall trajectory shift.
16 May
LENZ Therapeutics receives a downgrade that signals grim prospects and negative pressure on its stock performance and market outlook. Analyst downgrade directly undermines investor confidence and is likely to pressure LENZ stock price and future prospects.
14 May
LENZ Therapeutics (NASDAQ:LENZ) recently reported results, leading analysts to cut their earnings estimates and price targets. Analyst estimate cuts post-reporting indicate moderately noticeable pressure on financial performance and market sentiment.
12 May
LENZ Therapeutics Inc. reported strong prescription growth in Q1 2026 earnings call highlights amid ongoing challenges. Strong prescription growth highlights accelerating market adoption and revenue potential for LENZ.
LENZ Therapeutics, Inc. held Q1 2026 earnings call detailing financial results, operational updates and outlook. Quarterly earnings releases typically provide moderate short-term influence on valuation and sentiment.
11 May
LENZ Therapeutics released Q1 earnings call highlights covering financial results, operational updates, and forward-looking guidance. Q1 earnings call highlights detail financial performance and strategic developments that significantly shape LENZ Therapeutics' trajectory and investor sentiment.
LENZ Therapeutics, Inc. (LENZ) reported a Q1 net loss but beat revenue estimates. Beating revenue estimates despite Q1 loss moderately boosts financial performance and investor sentiment.
LENZ Therapeutics reported first quarter 2026 financial results and recent corporate highlights. Quarterly financial results affect key financial performance metrics and investor sentiment.
20 Apr
LENZ Therapeutics submitted a Marketing Authorization Application to the UK's Medicines and Healthcare products Regulatory Agency for VIZZ® to treat presbyopia. MAA submission to MHRA represents a major regulatory milestone advancing VIZZ® toward UK approval and potential revenue expansion.
1 Apr
President of LENZ Therapeutics, Inc. (LENZ) increases stock holdings by 57%. President's 57% stock increase signals strong insider confidence, likely boosting short-term market sentiment without altering core operations.
29 Mar
Consensus EPS estimates for LENZ Therapeutics, Inc. (NASDAQ:LENZ) just fell dramatically. Dramatic drop in consensus EPS estimates signals sharply lowered profitability expectations, significantly harming investor sentiment and market performance.
27 Mar
Lenz Therapeutics (LENZ) stock plummeted nearly 20% this week. Nearly 20% weekly stock drop points to moderately noticeable short-term influence on financial performance and investor sentiment.
25 Mar
LENZ Therapeutics, Inc. released Q4 2025 earnings call summary highlighting financial results, operational updates, and future outlook. Q4 earnings call summary details financial performance, strategic updates, and guidance that significantly shape LENZ's market trajectory and investor sentiment.
24 Mar
LENZ Therapeutics Inc reported a strong cash position in Q4 2025 earnings call highlights, emphasizing financial stability amid ongoing operations. Strong cash position signals robust financial health, likely boosting investor confidence and supporting LENZ's growth trajectory.
LENZ Therapeutics reported Q4 2023 financials with $69.6 million cash position providing runway into 2026, no revenue as pre-commercial stage, successful NDA submission for LNZ100 presbyopia eye drop in March 2024 targeting Q4 2024 approval and 2025 launch, positive Phase 3 CLARITY data, and upcoming commercial preparations. Q4 earnings highlights underscore NDA submission, strong cash runway, and near-term commercialization path for LNZ100, poised to significantly boost valuation and market position.
LENZ Therapeutics stock plunged over 60% after the FDA notified the company that its NDA for LNZ100 presbyopia eye drops is not sufficiently complete for substantial review, requiring resubmission with additional data on manufacturing and controls. FDA's determination of incomplete NDA filing significantly delays LENZ's lead product approval and commercialization timeline, hammering stock value and investor sentiment.
LENZ Therapeutics announced fourth quarter and full-year 2025 financial results, alongside recent corporate highlights. Q4 and full-year financial results with corporate highlights signal major updates on performance and strategy, likely shifting investor sentiment and trajectory.
10 Mar
LENZ Therapeutics submitted a Marketing Authorization Application to the European Medicines Agency for VIZZ® to treat presbyopia. MAA submission to EMA represents a major regulatory milestone for VIZZ, enabling potential European market entry and significantly enhancing LENZ's growth trajectory.
14 Jan
LENZ Therapeutics, Inc. has partnered with actress Sarah Jessica Parker to launch the 'Make it VIZZable' consumer campaign. This initiative aims to raise awareness and promote the company's VIZZ product, which is designed to address specific health needs. The collaboration with Parker is expected to enhance the campaign's visibility and reach, leveraging her influence to connect with a broader audience. The campaign's collaboration with a high-profile celebrity may moderately influence brand awareness and market sentiment.
12 Jan
LENZ Therapeutics, Inc. has launched its VIZZ product, which is expected to drive momentum for the company. Additionally, a new agreement with Lunatus is anticipated to enhance its market position. These developments suggest a positive outlook for LENZ's valuation and future performance. The launch of VIZZ and the agreement with Lunatus are significant strategic moves that could alter the company's trajectory and investor sentiment.
11 Jan
LENZ Therapeutics, Inc. (LENZ) experienced a 7.1% decline following the announcement of a deal with VIZZ Middle East and the release of early launch data. Investors are questioning whether the bullish outlook for the company has shifted due to these developments. The deal and early launch data may moderately influence investor sentiment and financial performance.
8 Jan
Analysts predict that LENZ Therapeutics, Inc. (NASDAQ:LENZ) will reach breakeven soon, indicating a positive outlook for the company's financial performance. The expectation is based on recent developments and market conditions that may favor the company's growth trajectory. Analysts' expectations of breakeven suggest a moderately noticeable influence on the company's financial performance.
7 Jan
LENZ Therapeutics, Inc. reported its preliminary unaudited financial results for the fourth quarter of 2025, highlighting key metrics and recent corporate developments. The company continues to advance its pipeline and strategic initiatives, positioning itself for future growth in the biopharmaceutical sector. The preliminary financial results and corporate updates indicate moderate influence on the company's financial performance and strategic direction.